Ocean Biomedical (NASDAQ: OCEA) Shares Detailed Research Data on Anti-Tumor Pathway Discoveries and Their Potential for Treatment of Non-Small Cell Lung Cancer, Metastatic Melanoma, and Glioblastoma by Scientific Co-founder
In his talk, Dr. Elias focused on his lab’s groundbreaking work on understanding the development and progression of lung cancer, especially the role of Chitinase 3-like-1 (CHI3L1).
- In his talk, Dr. Elias focused on his lab’s groundbreaking work on understanding the development and progression of lung cancer, especially the role of Chitinase 3-like-1 (CHI3L1).
- He also shared details of his novel therapeutic discoveries that show the efficacy of monospecific and bispecific antibodies against CHI3L1 and PD-1 as therapies for non-small cell lung cancer, and glioblastoma multiforme.
- Ocean Biomedical is currently working to move these antibody therapeutic discoveries towards Phase 1 clinical trials.
- In his recent talk, Dr. Elias shared details of his team’s discoveries of the role CHI3L1 in regulating primary and metastatic lung cancer, glioblastoma multiforme, and broader oncogenic pathways.